Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652351 | 0.91 | SMN1; SMN2 (0.46) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL10645199 | 0.89 | CTSV (0.56) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL10651184 | 0.86 | MAPT (0.51) | MEN1KMT2AMAPTARCTSV | |
| SCHEMBL10647647 | 0.86 | KMT2A (0.49) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL10643617 | 0.84 | ADAMTS5 (0.44) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL10645202 | 0.84 | MAPT (0.44) | MEN1KMT2AMAPTLMNANPC1 | |
| SCHEMBL3169532 | 0.82 | MAPT (0.54) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL7499740 | 0.81 | MEN1 (0.64) | MEN1KMT2AMAPTARCTSV | |
| SCHEMBL3178068 | 0.80 | KMT2A (0.47) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL10652344 | 0.80 | HRH3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2008016661-A2 | MORPHOLINO COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES AND CANCERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016665-A2 | IMIDAZOACRIDINE COMPOUNDS FOR TREATING FLT3 -MEDIATED DISORDERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-6664263-B2 | Potent unsymmetrical DNA bifunctional intercalators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-16 | — | — | US | disclosed |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEARTMENT OF | 2003-10-30 | — | — | US | disclosed |
| EP-1265898-B1 | 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1265898-A2 | 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066545-A2 | 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-0145226-B1 | SUBSTITUTED 1-AMINO-4-NITRO-ACRIDINONES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0138302-B1 | PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4626540-A | Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them | WARNER-LAMBERT COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4621086-A | Method of treating leukemia with pyrazolo[3,4,5-kl]acridines | WARNER-LAMBERT COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4588730-A | Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials | WARNER-LAMBERT COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4555572-A | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0145226-A2 | Substituted 1-amino-4-nitro-acridinones, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0138302-A1 | Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | MEN1 187/4885KMT2A 629/4885MAPT 4562/4885 |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | MKI67, CDKN1A, CCNA1 | MEN1 810/4885KMT2A 3775/4885MAPT 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.